Prospective evaluation of non-invasive biomarkers of kidney function and musculoskeletal status with checkpoint inhibitor therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030999

Enrollment

200

Registered

2023-01-04

Start date

2023-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

to prospectively evaluate kidney function and musculoskeletal status in patients receiving a checkpoint inhibitor therapy

Interventions

Group 1: Patients with checkpoint inhibitor therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Malignant disease with indication for checkpoint inhibitor therapy according to current guidelines

Exclusion criteria

Exclusion criteria: Not capable of consent patients Participation in clinical study with blinded use of immune therapy

Design outcomes

Primary

Measure	Time frame
Kidney failure	—

Secondary

Measure	Time frame
Musculoskeletal complaints	—

Countries

Germany

Contacts

Public ContactBjörn Tampe

Universitätsmedizin Göttingen

bjoern.tampe@med.uni-goettingen.de+49 551 39 10575

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026